Quantcast

Latest European Association for the Study of the Liver Stories

2012-03-15 22:49:46

The European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) today publish their first joint Clinical Practice Guidelines (CPGs) on the management of hepatocellular carcinoma (HCC). The EASL-EORTC guidelines define the use of surveillance, diagnosis and therapeutic strategies recommended for patients with HCC. HCC is the most common form of liver cancer, representing more than 90% of primary liver cancers and an...

2012-02-07 14:49:41

The first European Clinical Practice Guidelines (CPGs) for the diagnosis and management of Wilson's disease are published today by the European Association for the Study of the Liver (EASL) on the EASL website -- www.easl.eu.(1) Developed to assist physicians and healthcare providers in the clinical decision making process, the guidelines describe best practice for the diagnosis and treatment of patients with Wilson's disease -- a rare genetic(2) disorder that, if left untreated, is fatal....

2011-03-07 15:29:00

CAMBRIDGE, Mass., March 7, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that two abstracts have been accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL, March 30- April 3, 2011 in Berlin, Germany). Full abstracts can now be viewed at the EASL website at www.easl.eu. The...

2010-12-10 01:00:00

ATHENS, December 10, 2010 /PRNewswire/ -- - New Research and Measures to Tackle Societal Alcohol Consumption Announced at Liver Disease Conference Europe is failing to deal with the life-threatening effects of excessive and regular alcohol consumption on its citizens' health. Severe diseases, such as liver cirrhosis, are growing at an alarming rate and are affecting people at a younger age than in the past.[1] Since a number of current policies have not been successful in...

2010-04-19 08:00:00

SAN FRANCISCO and VIENNA, April 19 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical-stage cancer biotherapeutics company, today announced the presentation of positive interim data from its randomized Phase 2 clinical trial using JX-594 for the treatment of advanced hepatocellular carcinoma (HCC), or liver cancer, at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria. The study results, presented today...

2010-04-16 13:53:12

Results show highly significant dose dependent response Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH "“ the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell...

2010-03-16 08:44:00

CAMBRIDGE, Mass., March 16 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that four abstracts have been accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL, April 14-18, 2010 in Vienna, Austria). Full abstracts can now be viewed at the EASL website at www.easl.eu. The...

2009-04-27 01:00:00

Final results from three large PEGINTRON(TM) clinical studies address key questions in the treatment of hepatitis C COPENHAGEN, Denmark, April 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that final results of three large PEGINTRON(TM) (peginterferon alfa-2b) clinical studies address longstanding questions in the hepatitis C research community and provide important insights. The results of the studies, involving a total of more than 2,700 patients,...

2009-04-25 11:30:00

- Combination of R7227, protease inhibitor, and R7128, nucleoside polymerase inhibitor, shows significant potency in reducing viral load in patients with hepatitis C - NUTLEY, N.J., BRISBANE, Calif., and PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Roche, InterMune, Inc. (Nasdaq: ITMN) and Pharmasset (Nasdaq: VRUS) today announced the first results from their innovative, interferon-free regimen of direct acting antiviral (DAA) combination therapy for the treatment of patients...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.